-
Product Insights
Tardive Dyskinesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Tardive Dyskinesia - Drugs In Development, 2023’, provides an overview of the Tardive Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tardive Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Dyskinesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Dyskinesia - Drugs In Development, 2023’, provides an overview of the Dyskinesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – alpha-dihydrotetrabenazine in Tardive Dyskinesia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - alpha-dihydrotetrabenazine in Tardive Dyskinesia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. alpha-dihydrotetrabenazine in Tardive Dyskinesia Drug Details: Alpha-dihydrotetrabenazine is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CPL-409116 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CPL-409116 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CPL-409116 in Idiopathic Pulmonary Fibrosis Drug Details:CPL-409116 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-501 in Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-501 in Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-501 in Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – alpha-dihydrotetrabenazine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry alpha-dihydrotetrabenazine Drug Details Alpha-dihydrotetrabenazine is under development for the treatment of tardive dyskinesia. The...
-
Product Insights
Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape. Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include...
-
Analyst Opinions
Popcorn Market in the United States to 2020
The report presents detailed data on consumption trends in the Popcorn category in United States, analyzing consumption volumes and values at segment level. It also provides indispensable data on distribution channels along with latest industry news and mergers & acquisitions (of Savory Snacks market). Furthermore the report enables readers to examine the components of change in the industry by looking at historic and future growth patterns.